Patents Assigned to Pharmacia & Upjohn Company
  • Anthelmintic and insecticidal compositions
    Patent number: 7071215
    Abstract: Novel anthelmintic compositions containing thiophene derivatives as active ingredients are disclosed.
    Type: Grant
    Filed: October 16, 2003
    Date of Patent: July 4, 2006
    Assignee: Pharmacia & Upjohn Company LLC
    Inventor: Byung Hyun Lee
  • METHOD OF TREATING MIGRAINE HEADACHES
    Publication number: 20060142289
    Abstract: Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.
    Type: Application
    Filed: February 7, 2006
    Publication date: June 29, 2006
    Applicant: PHARMACIA & UPJOHN COMPANY
    Inventors: Erik Wong, Saeeduddin Ahmed, Robert Marshall, Robert McArthur, Duncan Taylor
  • Human ion channel proteins
    Patent number: 7067626
    Abstract: The present invention provides novel ion channel polypeptides and polynucleotides that identify and encode them. In addition, the invention provides expression vectors, host cells and methods for their production. The invention also provides methods for the identification of ion channel agonists/antagonists, useful for the treatment of human diseases and conditions.
    Type: Grant
    Filed: July 5, 2001
    Date of Patent: June 27, 2006
    Assignee: Pharmacia & Upjohn Company
    Inventors: Christopher W. Benjamin, Steven L. Roberds, Alla M. Karnovsky, Cara L. Ruble
  • Diaminediols for the treatment of Alzheimer's disease
    Patent number: 7067542
    Abstract: The present invention relates to compounds of formula (I): useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
    Type: Grant
    Filed: July 10, 2002
    Date of Patent: June 27, 2006
    Assignee: Pharmacia & Upjohn Company
    Inventors: Heinrich Josef Schostarez, Robert A. Chrusciel
  • Macrocycles useful in the treatment of Alzheimer's disease
    Patent number: 7067507
    Abstract: The present invention is macrocycles of the formula (X): for treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme for the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
    Type: Grant
    Filed: June 13, 2002
    Date of Patent: June 27, 2006
    Assignee: Pharmacia & Upjohn Company
    Inventors: Shon R. Pulley, James P. Beck, Ruth E. TenBrink, Jon S. Jacobs
  • Method of treating peripheral neuropathy
    Publication number: 20060135520
    Abstract: Methods and compositions for treating humans suffering from or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.
    Type: Application
    Filed: February 7, 2006
    Publication date: June 22, 2006
    Applicant: PHARMACIA & UPJOHN COMPANY
    Inventors: Erik Wong, Saeeduddin Ahmed, Robert Marshall, Robert McArthur, Duncan Taylor
  • METHOD OF TREATING CHRONIC FATIGUE SYNDROME
    Publication number: 20060135521
    Abstract: Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.
    Type: Application
    Filed: February 7, 2006
    Publication date: June 22, 2006
    Applicant: PHARMACIA & UPJOHN COMPANY
    Inventors: Erik Wong, Saeeduddin Ahmed, Robert Marshall, Robert McArthur, Duncan Taylor
  • Method of treating chronic fatigue syndrome
    Publication number: 20060128705
    Abstract: Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.
    Type: Application
    Filed: February 7, 2006
    Publication date: June 15, 2006
    Applicant: PHARMACIA & UPJOHN COMPANY
    Inventors: Erik Wong, Saeeduddin Ahmed, Robert Marshall, Robert McArthur, Duncan Taylor
  • Aminediols for the treatment of Alzheimer's disease
    Patent number: 7053109
    Abstract: The present invention relates to compounds of formula (I): useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
    Type: Grant
    Filed: July 10, 2002
    Date of Patent: May 30, 2006
    Assignee: Pharmacia & Upjohn Company
    Inventors: Heinrich Josef Schostarez, Robert Alan Chrusciel
  • Mannich base prodrugs of 3-(pyrrol-2-yl-methylidene)-2-indolinone derivatives
    Patent number: 7053113
    Abstract: The present invention is directed to Mannich base prodrugs of certain 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives that modulate the activity of protein kinases (“PKs”). Pharmaceutical compositions comprising these compounds, methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.
    Type: Grant
    Filed: December 24, 2003
    Date of Patent: May 30, 2006
    Assignees: Sugen, Inc., Pharmacia & Upjohn Company LLC
    Inventors: Malcolm Wilson Moon, Walter Morozowich, Ping Gao, Peng Cho Tang
  • Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound
    Patent number: 7049443
    Abstract: The present invention is directed to novel amide-containing compounds which have an improved solubility and a method of improving the solubility of amide-containing compounds. The amide-containing compounds include oxazolidinone compounds and the bioavailability of these oxazolidinone compounds is improved by improving the solubility thereof.
    Type: Grant
    Filed: July 12, 2002
    Date of Patent: May 23, 2006
    Assignee: Pharmacia & Upjohn Company
    Inventor: Jackson B. Hester, Jr.
  • Inhibitors of HCV NS5B polymerase
    Patent number: 7041690
    Abstract: The present invention provides compounds of Formula I, compositions and methods that are useful for treating viral infections and associated diseases, particularly HCV infections and associated diseases
    Type: Grant
    Filed: June 30, 2003
    Date of Patent: May 9, 2006
    Assignee: Pharmacia & Upjohn Company, LLC
    Inventors: Barry Craig Finzel, Hua Gao, Meredith L. Greene, Rebecca J. Gross, Richard Allen Nugent, Jeffrey A. Pfefferkorn
  • Alzheimer's disease secretase, APP substrates therefor, and uses thereof
    Patent number: 7041473
    Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the ? secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cell and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
    Type: Grant
    Filed: April 12, 2000
    Date of Patent: May 9, 2006
    Assignee: Pharmacia & Upjohn Company
    Inventors: Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
  • 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
    Patent number: 7034049
    Abstract: Compounds which are 3-amino-pyrazole derivatives represented by formula (I) wherein R is C3–C6 cycloalkyl group optionally substituted by a straight or branched C1–C6 alkyl or arylalkyl group; R1 is a straight or branched C1–C6 alkyl, C2–C4 alkenyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, arylalkyl, arylcarbonyl, aryloxyalkyl or arylalkenyl group, each of which may be optionally further substituted as indicated in the description; or a pharmaceutically acceptable salt thereof. The compounds are useful for the treatment of cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases or neurodegenerative diseases.
    Type: Grant
    Filed: May 5, 2000
    Date of Patent: April 25, 2006
    Assignees: Pharmacia Italia S.p.A., Pharmacia & Upjohn Company LLC
    Inventors: Paolo Pevarello, Paolo Orsini, Gabriella Traquandi, Mario Varasi, Edward L. Fritzen, Martha A. Warpehoski, Betsy S. Pierce, Maria Grabriella Brasca
  • 1,2,3,4,5,6-Hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
    Patent number: 7030109
    Abstract: The present invention discloses radioligands of 9-arylsulfone of the formula (X) or a pharmaceutically acceptable salt or enantiomer thereof, which are useful in diagnosing depression, obesity and other CNS disorders.
    Type: Grant
    Filed: April 25, 2003
    Date of Patent: April 18, 2006
    Assignee: Pharmacia & Upjohn Company
    Inventors: Eric Jon Jacobsen, Kalpana M. Merchant
  • Indoles and indolines having 5-HT activity
    Patent number: 7022694
    Abstract: The present invention provides compounds of Formula (I): wherein R1, R2, R3, R4, R5, R6 and --- have any of the values defined in the specification, as well as pharmaceutical compositions comprising the compounds. The invention also provides therapeutic methods as well as processes and intermediates useful for preparing compounds of Formula (I). The compounds are useful as 5-HT ligands.
    Type: Grant
    Filed: July 11, 2002
    Date of Patent: April 4, 2006
    Assignee: Pharmacia & UpJohn Company
    Inventors: Jian-Min Fu, Jeanette Kay Morris, Arthur Glenn Romero
  • Indolone oxazolidinones and derivatives thereof
    Patent number: 7012088
    Abstract: The present invention provides antibacterial agents of formula I described herein and intermediates for their preparation.
    Type: Grant
    Filed: January 22, 2004
    Date of Patent: March 14, 2006
    Assignee: Pharmacia & Upjohn Company
    Inventor: Toni-Jo Poel
  • 1-(Pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
    Patent number: 7008943
    Abstract: The present invention is directed to 1-pyrrolidin-1-ylmethyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives that modulate the activity of protein kinases (“PKs”). Pharmaceutical compositions comprising these compounds, methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.
    Type: Grant
    Filed: May 5, 2003
    Date of Patent: March 7, 2006
    Assignee: Pharmacia & Upjohn Company
    Inventors: Malcolm Wilson Moon, Walter Morozowich, Ping Gao
  • Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
    Patent number: 7005421
    Abstract: According to the invention there is provided a sterile, pyrogen-free, ready-to-use solution of an anthracycline glycoside, especially doxorubicin, which consists essentially of a physiologically acceptable salt of an anthracycline glycoside dissolved in a physiologically acceptable solvent therefor, which has not been reconstituted from a lyophilizate and which has a pH of from 2.5 to 6.5. The solution of the invention is particularly advantageous for the administration by injection of the anthracycline glycoside drugs. e.g. doxorubicin, in the treatment of both human and animal tumors.
    Type: Grant
    Filed: June 4, 2003
    Date of Patent: February 28, 2006
    Assignee: Pharmacia & Upjohn Company
    Inventors: Gaetano Gatti, Diego Oldani, Giuseppe Bottoni, Carlo Confalonieri, Luciano Gambini, Roberto De Ponti
  • Tolterodine salts
    Patent number: 7005449
    Abstract: The present invention concerns novel pharmaceutically active compounds, pharmaceutical compositions containing the same, the compounds for use as medicaments, and use of the compounds for the manufacture of specific medicaments. The present invention also concerns a method of treatment involving administration of the compounds. Specifically, the compounds are pharmaceutically acceptable salts of tolterodine or hydroxytolterodine, wherein the salt is of an acid selected from the group consisting of aliphatic mono- and dicarboxylic acids comprising from 7 to 24 carbon atoms, alkanedisulfonic acids comprising from 2 to 4 carbon atoms, naphthoic acid derivatives comprising from 11 to 27 carbon atoms, maleic acid and fumaric acid.
    Type: Grant
    Filed: April 23, 2002
    Date of Patent: February 28, 2006
    Assignee: Pharmacia & Upjohn Company
    Inventors: Michael Hawley, Satish Kumar Singh, Walter Morozowich, Mark P. Warchol